Home > Drugs A – Z > Peginterferon Alfa-2b (Injection)
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Peginterferon Alfa-2b (Injection)

Treats hepatitis C.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Peginterferon alfa-2b injection is a synthetic (man-made) version of substances normally produced in the body to fight infection. Peginterferon alfa-2b injection is used alone or together with ribavirin and another drug called a hepatitic C virus (HCV) NS3/4A protease inhibitor (such as telaprevir or boceprevir) to treat chronic hepatitis C infection. It is used for patients who have never been… Read more
Brand names include
PEG-Intron, PEGIntron, Peg Intron RP, Sylatron
Drug classes About this
Antineoplastic Agent, Immunological Agent

What works? Research summarized

Evidence reviews

Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naive patients with hepatitis C virus infection: meta-analysis of randomized controlled trials

BACKGROUND: Pegylated interferon (PEGIFN) and ribavirin combination is the standard of care for the treatment of chronic hepatitis C virus (HCV) infection. Studies comparing the efficacy and safety of PEGIFN alfa-2a and PEGIFN alfa-2b in treatment-naïve HCV-infected patients have shown conflicting results.

Management of Chronic Hepatitis B

Synthesize evidence of the natural history of chronic hepatitis B (CHB) and effects and harms of antiviral drugs on clinical, virological, histological, and biochemical outcomes.

Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation

To assess the clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C virus (HCV) in three specific patient subgroups affected by recent licence changes: those eligible for shortened treatment courses [i.e. those with low viral load (LVL) and who attained a rapid virological response (RVR) at 4 weeks of treatment], those eligible for re-treatment following previous non-response or relapse, and those co-infected with human immunodeficiency virus (HIV).

See all (11)

Summaries for consumers

Treating Chronic Hepatitis C: A Review of the Research for Adults

This summary will discuss treatment options for chronic hepatitis C. It will tell you about research on how well medicines for chronic hepatitis C work. It will also tell you about research on the side effects of these medicines. It does not discuss screening and diagnosis of hepatitis C. This summary can help you talk with your doctor about which treatment might be best for you.

Comparing Pegylated Interferons for Hepatitis C

How do pegylated interferons compare in treating chronic hepatitis C?

PubMed Health Blog...

read all...